The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview.
On 8 February 2003, the second in a series of meetings in honor of John E. Bennett, M.D., was convened in New York City. A report from the previous meeting was published in 2003. The goal of this second meeting was to discuss the design of clinical trials in prophylaxis and combination therapy. This supplement presents 12 articles by leading clinicians who are currently active in trials in this area and presents a current view of the unmet needs and challenges.
Rex
John H
JH
AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom. john@rexweb.org
Wingard
John R
JR
Wenzel
Richard
R
Herbrecht
Raoul
R
Sobel
Jack
J
Edwards
John E
JE
D000935:Antifungal Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D009181:Mycoses / Q000188:drug therapy / Q000517:prevention & control*; D011315:Preventive Medicine; D012107:Research Design
D000935:Antifungal Agents